Sandoz

Novartis may have found a buyer for Sandoz; report

Just a few weeks after Novartis revealed it was considering a sale of its generics business Sandoz, there are reports that a potential buyer has already come forward. A report by German newspaper Handelsblatt says that investment group EQT and the German Struengmann family are considering a CHF 20 billion ($21.6 billion) bid for Sandoz …

Novartis may have found a buyer for Sandoz; report Read More »

Swiss socialists say government should buy Sandoz

Switzerland’s Social Democratic Party has argued that the government should step in and acquire Novartis’ generics unit Sandoz if the company decides to sell it, according to local press reports. The largest left-leaning party in Switzerland said that national ownership of Sandoz would democratise the production and development of new medicines, maintain a stable supply …

Swiss socialists say government should buy Sandoz Read More »

Sandoz’s Pierre Bourdage on biosimilars: the pharmaphorum podcast

In the latest episode of the podcast Dominic Tyer speaks with Pierre Bourdage, who’s global head of biopharmaceuticals at Sandoz about the big issues in biosimilars. They look at how biosimilars are changing healthcare and what the market looks like today, as well as Sandoz’s involvement in the area and the company’s future plans in …

Sandoz’s Pierre Bourdage on biosimilars: the pharmaphorum podcast Read More »

Top 20 Generics Pharma Companies Based On 2020 Revenue

Generic medicines are the backbone of the healthcare system. The expiry of patents of branded drugs is the essential tool in the development of generic medicines. Generics medicines are identical to the innovator medicine in strength, effect, dosage form, and route of administration. Generic drugs are cheap and equally safe and effective as the branded …

Top 20 Generics Pharma Companies Based On 2020 Revenue Read More »

Novartis looking into future of its Sandoz’ generics business

Novartis revealed today that it may consider divesting its generic medicines subsidiary Sandoz – amongst other options – which would further narrow its focus to innovative medicines. The company said in its third-quarter results statement that it was weighing options for Sandoz to “maximise shareholder value,” adding that could include retaining the business or a …

Novartis looking into future of its Sandoz’ generics business Read More »

Insights+ Key Biosimilars Events of September 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of September, Sandoz entered into a commercialization and license …

Insights+ Key Biosimilars Events of September 2021 Read More »

PharmaShots’ Key Highlights of Third Quarter 2021

The third quarter of 2021 highlights the approvals, clinical data & acquisitions. The new alliance observed in third quarter includes AzurRx signed a reverse triangular merger agreement to acquired First Wave Bio for ~$229M The key highlights of the big acquisition in this quarter includes Merck acquired Acceleron for ~$11.5B, Baxter acquired Hillrom for ~$10.5B, …

PharmaShots’ Key Highlights of Third Quarter 2021 Read More »

Sandoz Enters into a Commercialization and License Agreement with Bio-Thera to Commercialize BAT1706, a Proposed Biosimilar Avastin (bevacizumab)

Shots: Bio-Thera to receive an up front, milestones along with royalties on product sales & will be responsible for the development, manufacturing, supply of BAT1706 Sandoz to get rights for the commercialization of the therapy upon approval in the US, EU, Canada, and other countries. Bio-Thera’s BAT1706 has completed extensive biosimilar studies, including a global …

Sandoz Enters into a Commercialization and License Agreement with Bio-Thera to Commercialize BAT1706, a Proposed Biosimilar Avastin (bevacizumab) Read More »

Insights+ Key Biosimilars Events of August 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of August, Samsung Bioepis’ Byooviz (biosimilar, ranibizumab) received EC’s …

Insights+ Key Biosimilars Events of August 2021 Read More »

PharmaShots’ Key Highlights of Second Quarter 2021

The second quarter of 2021 witnesses major acquisitions, approvals, and clinical data. There are major alliances in this quarter which include Merck signed ~$1.2B supply agreement with US Government for Molnupiravir to treat COVID-19 The big acquisition took place during the quarter including Microsoft acquired Nuance for ~$19.7B, MorphoSys acquired Constellation for ~$1.7B Our team …

PharmaShots’ Key Highlights of Second Quarter 2021 Read More »

Insights+ Key Biosimilars Events of May 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of May, Samsung initiated patient enrollment in the P-III …

Insights+ Key Biosimilars Events of May 2021 Read More »

The US Supreme Court Denies Sandoz’s Petition for Erelzi (biosimilar, etanercept)

Shots: The US Supreme Court has denied Sandoz’ petition to review Federal Circuit’s July 2020 decision concerning the Sandoz biosimilar Erelzi (etanercept-szzs) for the reference product, Enbrel (etanercept) The company was unable to launch the product in the US due to patent litigation. The affordable biosimilar will not be available in the US till 2029 …

The US Supreme Court Denies Sandoz’s Petition for Erelzi (biosimilar, etanercept) Read More »

PharmaShots Weekly Snapshots (May 03 – 07, 2021)

AstraZeneca Reports Results of Imfinzi (durvalumab) and Imfinzi + Tremelimumab in P-III POSEIDON Study as 1L Treatment for Stage IV Non-Small Cell Lung Cancer Published: May 7, 2021 | Tags: AstraZeneca, Imfinzi, durvalumab, Tremelimumab, P-III, POSEIDON Study, Stage IV Non-Small Cell Lung Cancer Merck and Fusion Pharmaceuticals Enter into a Clinical Collaboration for FPI-1434 + …

PharmaShots Weekly Snapshots (May 03 – 07, 2021) Read More »

Insights+ Key Biosimilars Events of April 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of April, Biocon and Viatris received EC’s approval for …

Insights+ Key Biosimilars Events of April 2021 Read More »

Sandoz Initiates Patient Enrolment of Proposed Biosimilar Aflibercept in P-III MYLIGHT Study for Neovascular Age-Related Macular Degeneration

Shots: The company starts enrolling patients in the P-III MYLIGHT study to evaluate the safety and efficacy of biosimilar aflibercept vs Eylea in patients with nAMD for 48wks. The study is expected to enroll 460 patients across 20 countries The study is a part of a biosimilar development program that includes analytical, pre/ clinical data. …

Sandoz Initiates Patient Enrolment of Proposed Biosimilar Aflibercept in P-III MYLIGHT Study for Neovascular Age-Related Macular Degeneration Read More »

Insights+ Key Biosimilars Events of February 2021

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients During the month of Feb, Biocon collaborated with CHAI to expand access …

Insights+ Key Biosimilars Events of February 2021 Read More »

Richard Francis on his Purespring plans: the pharmaphorum podcast

In this episode of the pharmaphorum podcast, our news editor Richard Staines talks to Richard Francis, who took over as CEO of gene therapy company Purespring Therapeutics earlier this month. Francis was previously CEO of Sandoz, Novartis’ generics and biosimilars division, where he led the development of biosimilars and also sat on the Swiss pharma …

Richard Francis on his Purespring plans: the pharmaphorum podcast Read More »

Novartis antibiotic retreat doesn’t stop Sandoz buying GSK drugs

Novartis exited novel antibiotics R&D three years ago, but is clearly still interested in the category – its Sandoz unit has just spent $350 million buying GlaxoSmithKline’s cephalosporin franchise.  The deal covers global rights to three brands – Zinnat (cefuroxime axetil), Zinacef (cefuroxime) and Fortum (ceftazidime) – which are sold in more than 100 markets …

Novartis antibiotic retreat doesn’t stop Sandoz buying GSK drugs Read More »

Novartis to Acquire GSK’s Cephalosporin Antibiotics Business

Shots: GSK to receive $350M at closing, along with ~$150M as milestones. The transaction is expected to close in H2’21 The transaction will allow GSK to prioritize and simplify its portfolio and invest in the company’s R&D pipeline and new product launches The agreement includes the global rights to three established brands (Zinnat, Zinacef and …

Novartis to Acquire GSK’s Cephalosporin Antibiotics Business Read More »

Insights+ Key Biosimilars Events of December 2020

Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency. Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and the patients. Hence, the providers are more likely to adopt biosimilars as a “reference …

Insights+ Key Biosimilars Events of December 2020 Read More »

PharmaShots Weekly Snapshots (Dec 14-18, 2020)

Sandoz to Launch Hyrimoz (biosimilar, adalimumab) in Canada Published: Dec 17, 2020 | Tags: Authorization, Biosimilar, canada, health, Humira, Hyrimoz, Launch, receives, Sandoz Amgen’s Riabni (biosimilar, rituximab) Receives the US FDA’s Approval for Multiple Diseases Published: Dec 17, 2020 | Tags: Adult, Amgen, approval, Biosimilar, CLL, GPA, MPA, NHL, patients, receives, RIABNI, Rituxan, Rituximab, rituximab-arrx, …

PharmaShots Weekly Snapshots (Dec 14-18, 2020) Read More »

Sandoz to Launch Hyrimoz (biosimilar, adalimumab) in Canada

Shots: Health Canada has authorized Hyrimoz on Nov 4, 2020 for marketing in Canada. Hyrimoz has been approved for use in all same indications as reference Humira, including rheumatology, gastroenterology and dermatology A patient support program will be available to patients treated with Hyrimoz providing guidance with reimbursement navigation, financial assistance, administrative support & education …

Sandoz to Launch Hyrimoz (biosimilar, adalimumab) in Canada Read More »

Top 20 Generics Pharma Companies Based On 2019 Revenue

The global generics pharmaceutical market has become an intimidating segment of the pharmaceutical drug market which continuously growing and increasing with its accessibility & benefits offered as efficient and economical drugs. Generics are approved copies of small molecule drugs that contain the same amount of active ingredients, dosage form, safety, strength, route of administration, quality, …

Top 20 Generics Pharma Companies Based On 2019 Revenue Read More »

The calm after the storm: How COVID-19 is making pharma more resilient

COVID-19 is proving to be the perfect storm in terms of the supply of pharmaceutical products. But learning how to overcome the challenges of 2020 will serve the industry well for years to come. As part of our EU Leader series, Christian Pawlu, head of strategy, portfolio and BD&L at Sandoz, told us about how …

The calm after the storm: How COVID-19 is making pharma more resilient Read More »

Novartis set to overcome $14 billion patent cliff say analysts

Novartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition in the coming years, analysts have said. Following a briefing with management, a team of analysts led by Peter Welford said that the big Swiss pharma will be propped up by its psoriasis and infectious diseases blockbuster …

Novartis set to overcome $14 billion patent cliff say analysts Read More »

Generic drugmaker Teva indicted in alleged price-fixing conspiracy leading consumers to be overcharged by $350M

The charges, filed in Philadelphia federal court, allege that Teva conspired with four other generic drug companies to fix prices, rig bids and allocate customers. Teva – which the Justice Department and New York’s state government also sued this month for unrelated allegations – said it rejected the allegations.

Teva charged in US price-fixing investigation

The US Department of Justice has charged Teva with conspiring with other pharma companies to fix prices for generic drugs. According to an indictment filed on Tuesday, the company participated in three counts of conspiracy from at least May 2013 until around December 2015, which could have resulted in customers being overcharged by at least …

Teva charged in US price-fixing investigation Read More »